



Supplementary Materials: HLA Expression in Relation to HLA Type in Classic Hodgkin Lymphoma Patients

Geok Wee Tan, Peijia Jiang, Ilja M. Nolte, Kushi Kushekhar, Rianne N. Veenstra, Bouke G. Hepkema, Ruth F. Jarrett, Anke van den Berg and Arjan Diepstra




Figure S1. Forest plots of significant cHL susceptibility or protective HLA alleles. Significant cHL-associated HLA alleles ($p < 0.01$) in meta-analysis, Netherlands cohort, and UK cohort for (A) cHL overall, (B) EBV- and (C) EBV+. Odds ratios with 95% confidence interval (CI) are shown and arrows represent clipping of lower or upper limits for CI.

Table S1. Number of subjects in meta-analysis and HLA expression analysis.

	Netherlands <i>n (%)</i>	UK <i>n (%)</i>	Combination <i>n (%)</i>
Meta-analysis			
Patients	337	502	839
EBV-	232 (68.8%)	348 (69.3%)	580 (69.1%)
EBV+	78 (23.1%)	154 (30.7%)	232 (27.7%)
EBV unknown	27 (8.0%)	0 (0%)	27 (3.2%)
Controls	347	7901	
HLA expression analysis			
Patients	254	84	338
EBV-	193 (76.0%)	57 (67.9%)	250 (74.0%)
EBV+	59 (23.2%)	27 (32.1%)	86 (25.4%)
EBV unknown	2 (0.8%)	0 (0%)	2 (0.6%)

Table S2. Frequencies of HLA alleles in patients and controls that were previously found to be suggestive ($p < 0.10$) in either cohort.

	Netherlands						UK					
	EBV+ cases	EBV- cases	All cases	Controls	EBV+ cases	EBV- cases	All cases	Controls				
HLA-A	78	232	337	7554	154	348	502	347				
A1	43	55%	70	30%	120	36%	2426	32%	98	64%	123	35%
A2	23	29%	123	53%	162	48%	4052	54%	55	36%	173	50%
A3	27	35%	56	24%	94	28%	2296	30%	34	22%	87	25%
A11	8	10%	30	13%	38	11%	713	9%	11	7%	37	11%
A19	12	15%	38	16%	55	16%	1620	21%	29	18%	77	22%
A28	4	5%	26	11%	33	10%	607	8%	7	5%	22	13%
HLA-B	78	229	333	7554	154	346	500	347				
B5	13	17%	33	14%	51	15%	784	10%	28	18%	10	3%
B7	25	32%	80	35%	115	35%	2233	30%	29	19%	134	39%
B8	24	31%	59	26%	88	26%	1932	26%	75	49%	97	28%
B12	12	15%	39	17%	55	17%	1765	23%	39	16%	96	21%
B15	10	13%	47	21%	61	18%	1434	19%	10	6%	50	14%
B27	1	1%	16	7%	18	5%	603	8%	6	4%	35	10%
B37	13	17%	10	4%	23	7%	270	4%	17	11%	11	3%
B40	13	17%	26	11%	44	13%	1339	18%	31	20%	27	8%
HLA-DR	78	231	336	6559	144	325	469	311				
DR2	25	32%	92	40%	127	38%	1967	30%	25	17%	142	44%
DR3	22	28%	55	24%	84	25%	1734	26%	66	46%	99	30%
DR4	23	29%	43	19%	69	21%	1969	30%	20	14%	57	18%
DR5	8	10%	60	26%	79	24%	1158	18%	12	8%	60	18%
DR6	28	36%	75	32%	113	34%	1989	30%	21	15%	48	15%
DR7	7	9%	25	11%	34	10%	1246	19%	26	18%	42	13%